Brand Name(s): Prozac; Sarafem
CAS nº: 54910-89-3
(floo 'ox e teen)
What is Fluoxetine?
Fluoxetine hydrochloride is an antidepressant drug used medically in the treatment of depression, obsessive-compulsive disorder, eating disorders such as bulimia nervosa, premenstrual dysphoric disorder, and panic disorder.
Fluoxetine can also be used to treat many other conditions, such as Attention-Deficit Hyperactivity Disorder (ADHD). It is sold under the brand names Prozac®, Symbyax® (compounded with olanzapine), Sarafem®, Fontex® (Sweden), Foxetin® (Argentina), Ladose® (Greece), Fluctin® (Austria, Germany), Prodep® (India), Fludac® (India) and Lovan® (Australia). Fluoxetine was derived from diphenhydramine, which is an antihistamine found to inhibit reuptake of the neurotransmitter "serotonin".
Compared to other popular Selective Serotonin Reuptake Inhibitors (SSRIs), fluoxetine has a strong energizing effect. This makes fluoxetine highly effective in treatment of clinical depression cases where symptoms like depressed mood and lack of energy exist. Although stimulating, it is also approved for a variety of anxiety disorders, including panic disorder and obsessive compulsive disorder.
Latest News
Growing Up to Prozac: Drug makes new neurons mature faster
Peter Pan won't be pleased to hear the latest theory about how Prozac works. A new study shows that...
[more]Aurobindo gets USFDA's tentative nod for two drugs
Home-grown drug firm Aurobindo Pharma has received a tentative approval from the US food and drug...
[more]Accelerated Neuronal Maturation with Antidepressant Treatment
Selective serotonin reuptake inhibitors (SSRIs) speed maturation of neurons as well as increase...
[more]Research Aims to Find Most Effective Family-Based Treatment for Anorexia
Experts no longer consider the family to be the cause of a young person’s onset of anorexia;...
[more]In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
Eli Lilly and Company strongly objects to implications in a New York Times article published...
[more]